Literature DB >> 22263068

Primary endpoints in cancer trials.

Kurt Ulm1.   

Abstract

Entities:  

Year:  2011        PMID： 22263068      PMCID： PMC3256504          DOI： 10.3978/j.issn.2072-1439.2011.02.02

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  6 in total

1.  Post-study therapy as a source of confounding in survival analysis of first-line studies in patients with advanced non-small-cell lung cancer.

Authors:  Vera D Zietemann; Tibor Schuster; Thomas Hg Duell
Journal:  J Thorac Dis       Date:  2011-06       Impact factor: 2.895

2.  Cheaper, faster, better: chasing the elusive clinical trial end point.

Authors:  Brad H Pollock
Journal:  J Clin Oncol       Date:  2009-04-20       Impact factor: 44.544

3.  Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables.

Authors:  James R Anderson; Kevin C Cain; Richard D Gelber
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544

4.  Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma.

Authors:  Frances A Shepherd; Ming-Sound Tsao
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

5.  Detecting an overall survival benefit that is derived from progression-free survival.

Authors:  Kristine R Broglio; Donald A Berry
Journal:  J Natl Cancer Inst       Date:  2009-11-09       Impact factor: 13.506

6.  Issues in using progression-free survival when evaluating oncology products.

Authors:  Thomas R Fleming; Mark D Rothmann; Hong Laura Lu
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544
  6 in total
  2 in total

Review 1.  Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?

Authors:  Lothar R Pilz; Christian Manegold; Gerald Schmid-Bindert
Journal:  Transl Lung Cancer Res       Date:  2012-03

2.  Disease-free time stratification in locally recurrent head and neck carcinoma after definitive radiotherapy or chemoradiotherapy.

Authors:  Philippe Gorphe; Antoine Moya-Plana; Joanne Guerlain; Yungan Tao; France Nguyen; Ingrid Breuskin; Pierre Blanchard; Stéphane Temam
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-10-14       Impact factor: 2.503
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.